Analyst Marie Thibault of BTIG reiterated a Buy rating on Ceribell, Inc., with a price target of $30.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Marie Thibault’s rating is based on Ceribell, Inc.’s strong financial performance and strategic initiatives. The company reported a significant year-over-year revenue increase of 31% for Q3, surpassing market expectations. This growth was driven by both product and subscription revenues, with gross margins also exceeding consensus estimates. Additionally, Ceribell added more new accounts than anticipated, indicating robust market penetration and customer adoption.
Furthermore, Ceribell has raised its sales outlook for 2025, reflecting confidence in its ongoing business momentum. The company is actively investing in pipeline initiatives, such as pilot programs for its newly cleared neonatal head cap and the development of a Delirium algorithm. These efforts are expected to enhance Ceribell’s competitive position and support future growth. The company’s strong cash position and strategic focus on expanding its market presence contribute to the Buy rating, with a price target of $30 based on projected sales multiples.
According to TipRanks, Thibault is an analyst with an average return of -5.8% and a 37.75% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Boston Scientific, Irhythm Technologies, and Embecta Corporation.